Aurobindo Pharma Q1 profit jumps 25% to record Rs 1,032 crore

Aurobindo Pharma reported a 25.2% year-on-year rise in consolidated net profit to Rs 1,032 crore for Q1FY27, with revenue up 16.3% to a record Rs 9,150 crore, driven by double-digit growth across key markets and new US product launches. EBITDA rose 20% to Rs 1,924 crore, with margin expanding to 21%. The board also approved merging two step-down subsidiaries into Eugia Pharma Specialities Ltd.